Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Epigenetic silencing including histone modifications and DNA methylation is an important tumorigenic mechanism. However, its role in cancer immunopathology and immunotherapy is poorly understood. Using human ovarian cancers as our model, here we show that enhancer of zeste homologue 2 (EZH2)-mediated histone H3 lysine 27 trimethylation (H3K27me3) and DNA methyltransferase 1 (DNMT1)-mediated DNA methylation repress the tumour production of T helper 1 (TH1)-type chemokines CXCL9 and CXCL10, and subsequently determine effector T-cell trafficking to the tumour microenvironment. Treatment with epigenetic modulators removes the repression and increases effector T-cell tumour infiltration, slows down tumour progression, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint blockade and adoptive T-cell transfusion in tumour-bearing mice. Moreover, tumour EZH2 and DNMT1 are negatively associated with tumour-infiltrating CD8(+) T cells and patient outcome. Thus, epigenetic silencing of TH1-type chemokines is a novel immune-evasion mechanism of tumours. Selective epigenetic reprogramming alters the T-cell landscape in cancer and may enhance the clinical efficacy of cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epigenetic reprogramming with shRNAs targeting DNA methyltransferase 1 (DNMT1) or pan-DNMT blockers like decitabine and guadecitabine has been shown to resemble EZH2 inhibition in its capacity to promote CXCL9 and CXCL10 secretion in various models of breast, lung, and ovarian carcinoma”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies have demonstrated that mutations in genes involved in the SWI-SNF chromatin remodeling complex may sensitize human tumors to ICIs and that treatment with an epigenetic modulator can potentiate the ICI-mediated antitumor response through increased production of chemokines responsible for recruiting CD8 + T cells (104-107).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [107]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The mTOR pathway has long been recognized to play a pivotal role in integrating signals at the cellular level and promote autoimmunity and carcinogenesis18,19.”
From Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation (2019) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“and TH1 cytokines”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Peng et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationIntratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Cited by
Items 501–600 of 1,000
Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges
Indini, A., Massi, D., Pirro, M., Roila, F., Grossi, F., Sahebkar, A., Glodde, N., Bald, T., & Mandalà, M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.06.005 · Cited by 42
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Xie, Z., Zhou, Z., Yang, S., Zhang, S., & Shao, B. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00126-2 · Cited by 42
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 40
“Frontiers in Immunology 08 cells, inhibit tumor progression, and enhance the efficacy of ICIs (120).”
BackgroundGuo, R., Li, J., Hu, J., Fu, Q., Yan, Y., Xu, S., Wang, X., & Jiao, F. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110417 · Cited by 40
Nigam, N., Bernard, B., Sevilla, S., Kim, S., Dar, M. S., Tsai, D., Robbins, Y. L., Burkitt, K., Sievers, C. M., Allen, C. T., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112823 · Cited by 38
“48 EZH2 silences the B2m promoter through H3K27me3 in MOC1 cells, and EZH2 inhibition enhances antigen presentation and responses to anti-PD-1 immunotherapy in the anti-PD-1 MOC1 resistant mouse model of HPV-negative HNSCC. 52 An important question to decipher is whether different repressive…”
Cracking the Codes behind Cancer Cells’ Immune Evasion
Mundhara, N., & Sadhukhan, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168899 · Cited by 41
Zhou, Z., Xu, J., Liu, S., Lv, Y., Zhang, R., Zhou, X., Zhang, Y., Weng, S., Xu, H. W., Ba, Y., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00630-9 · Cited by 40
“Therefore, the regulation of EZH2 to promote tumor immunity is multi-mechanism and multi-pathway [84–87].”
BackgroundP-stalk ribosomes act as master regulators of cytokine-mediated processes
Dopler, A., Alkan, F., Malka, Y., van der Kammen, R., Hoefakker, K., Taranto, D., Kocabay, N., Mimpen, I. L., Ramirez, C. F. A., Malzer, E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.039 · Cited by 42
Immune-Suppressing Cellular Elements of the Tumor Microenvironment
Fearon, D. T. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-034359 · Cited by 41
“The epigenetic silencing of CXCL9 and CXCL10 in tumors (Peng et al. 2015) may also be considered as support for the primacy of this node, although this phenomenon may merely reflect the relative absence in the tumor of cells, such as subsets of monocytes, macrophages, and DCs, that are programmed for expression of the…”
BackgroundInfluentialSun, W., Lv, S., Li, H., Cui, W., & Wang, L. (2018) · Genes · doi:10.3390/genes9120633 · Cited by 37
“Atezolizumab, which targets PD-L1, is in phase III/IV trial.”
BackgroundInfluentialCrosstalk between myeloid-derived suppressor cells and the immune system in prostate cancer
Sanaei, M., Salimzadeh, L., & Bagheri, N. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ru0819-150rr · Cited by 39
Yi, J., Shi, X., Xuan, Z., & Wu, J. I. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.031 · Cited by 37
“It has been shown that the human PRC2 complex inhibits CD8+ cytotoxic T cell recruitment to colon and ovarian cancers by repressing the expression of Th1-type chemokine genes CXCL9/CXCL10 in cancer cells (10, 11).”
BackgroundEZH2 as a mediator of treatment resistance in melanoma
Tiffen, J. C., Gallagher, S. J., Tseng, H., Filipp, F. V., Groth, B. F. D. S., & Hersey, P. (2016) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12481 · Cited by 39
“Moreover, this combination augmented the efficacy of immunotherapy with anti-PD1 (Peng et al., 2015).”
BackgroundEpigenetic mechanisms of tumor resistance to immunotherapy
Arenas-Ramirez, N., Sahin, D., & Boyman, O. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2908-7 · Cited by 36
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee, J., & Kim, E. H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1233376 · Cited by 39
“Additionally, epigenetic modifying agents, such as DNA methyltransferase inhibitors and histone deacetylases inhibitors, have the potential to significantly impact genes associated with tumor antigenicity, cytokine and chemokine production, as well as oncogenic or tumor-suppressive signaling (75, 94).”
BackgroundImmunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 43
Self-citationEpigenetic modulation of immunotherapy and implications in head and neck cancer
Zhou, L., Xu, N., Shibata, H., Saloura, V., & Uppaluri, R. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09944-0 · Cited by 37
Chi, A., He, X., Hou, L., Nguyen, N. P., Zhu, G., Cameron, R. B., & Lee, J. M. (2021) · Cancers · doi:10.3390/cancers13122924 · Cited by 37
Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
Llinàs‐Arias, P., Íñiguez-Muñoz, S., McCann, K. E., Voorwerk, L., Orozco, J. I. J., Ensenyat-Méndez, M., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021) · Cancers · doi:10.3390/cancers13164139 · Cited by 37
“Furthermore, high levels of the C-X-C motif chemokine ligands 9 and 10 (CXCL9 and CXCL10), C-C motif chemokine ligand 5 (CCL5), and IFN-y are associated with enhanced levels of CTLs in the TME [41].”
BackgroundTargeting the epigenome to reinvigorate T cells for cancer immunotherapy
Xiong, D., Zhang, L., & Sun, Z. (2023) · Military Medical Research · doi:10.1186/s40779-023-00496-2 · Cited by 51
“The Th1-type chemokines CXCL9/CXCL10 can be silenced by DNMT and EZH2 via increased methylation at the promoter region [32].”
BackgroundImmune Cell Migration to Cancer
Ryan, A. T., Kim, M., & Lim, K. (2024) · Cells · doi:10.3390/cells13100844 · Cited by 38
Histone demethylase JMJD3 at the intersection of cellular senescence and cancer
Perrigue, P. M., Najbauer, J., & Barciszewski, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.002 · Cited by 36
“Chemokine expression specific for T-cell tracking to human ovarian cancer tissues is controlled by the methylation status of H3K27 and polycomb-mediated silencing [68].”
Fazio, C., Covre, A., Cutaia, O., Lofiego, M. F., Tunici, P., Chiarucci, C., Cannito, S., Giacobini, G., Lowder, J. N., Ferraldeschi, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01443 · Cited by 37
Yuan, X., Liu, Y., Li, G., Lan, Z., Ma, M., Li, H., Kong, J., Sun, J., Hou, G., Hou, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0709 · Cited by 39
“HDACi and DNMTi promote the secretion of the epigenetically repressed chemokines and the subsequent trafficking of immune cells into tumor beds (16, 17).”
BackgroundMethodEffect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers
Wang, L., Qu, J., Zhou, N., Hou, H., Jiang, M., & Zhang, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110626 · Cited by 38
Nanomaterials Enhance the Immunomodulatory Effect of Molecular Targeted Therapy
Li, Z., Liu, Y., Fang, X., & Shu, Z. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s290346 · Cited by 35
Liao, Q., Yang, J., Ge, S., Chai, P., Fan, J., & Jia, R. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.11.009 · Cited by 39
Peng, L., Zhou, L., Li, H., Zhang, X., Su, L., Wang, K., Yang, M., Ma, X., Zhang, D., Xiang, S., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114003 · Cited by 37
Tumuluru, S., Godfrey, J. K., Cooper, A. B., Yu, J., Chen, X., MacNabb, B. W., Venkataraman, G., Zha, Y., Pelzer, B. W., Song, J. Y., et al. (2025) · Blood · doi:10.1182/blood.2024025355 · Cited by 42
Optimizing poly ( ADP ‐ribose) polymerase inhibition through combined epigenetic and immunotherapy
Prasanna, T., Wu, F., Khanna, K. K., Yip, D., Malik, L., Dahlstrom, J. E., & Rao, S. (2018) · Cancer Science · doi:10.1111/cas.13799 · Cited by 40
Protein tyrosine phosphatase nonreceptor type 2 controls colorectal cancer development
Katkeviciutė, E., Hering, L., Montalban‐Arques, A., Busenhart, P., Schwarzfischer, M., Manzini, R., Conde, J., Atrott, K., Lang, S., Rogler, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140281 · Cited by 36
“IFN-inducible chemokines, specifically CXCL9, CXCL10 and CXCL11 and their receptor CXCR3, have been described as important modulators of CD8 Tcell recruitment into tumor tissue (27-32).”
BackgroundParking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?
Evgin, L., & Vile, R. G. (2021) · Cancers · doi:10.3390/cancers13051106 · Cited by 34
“However, tumours may reduce levels of these ligands through epigenetic silencing or the co-expression of chemokine- cleaving proteases [53,54], and instead express CCL2 which recruits immature myeloid cells and TAMS [55–57].”
BackgroundPolycomb-group proteins in the initiation and progression of cancer
Zhao, X., & Wu, X. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.013 · Cited by 35
Treating lymphoma is now a bit EZ-er
Morin, R. D., Arthur, S. E., & Assouline, S. E. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002773 · Cited by 42
“In an ovarian cancer model, inhibiting EZH2 enhanced T-cell trafficking to the tumor and improved the therapeutic efficacy of programmed death ligand 1 (PDL1) checkpoint blockade.(48) Based on these findings, a phase 1b study combined tazemetostat with atezolizumab, a PDL1 inhibitor, in patients with relapsed/refracto…”
BackgroundTargeting the epigenetic processes to enhance antitumor immunity in small cell lung cancer
Luo, H., Shan, J., Zhang, H., Song, G., Li, Q., & Xu, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.018 · Cited by 35
Wang, M. Y., Liow, P., Guzman, M. I. T., & Qi, J. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00062 · Cited by 35
Kunert, A., van Brakel, M., van Steenbergen‐Langeveld, S., da Silva, M., Coulie, P. G., Lamers, C., Sleijfer, S., & Debets, R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502024 · Cited by 34
“hance expression of chemoattractants, increase CD8 T cell infiltration, and improve the therapeutic efficacy of adoptive T cell therapy (49).”
BackgroundKrill, L. S., Deng, W., Eskander, R. N., Mutch, D. G., Zweizig, S., Hoang, B. H., Ioffe, O. B., Randall, L. M., Lankes, H. A., Miller, D. S., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.003 · Cited by 34
Li, X., Tian, S., Shi, H., Ta, N., Ni, X., Bai, C., Zhu, Z., Chen, Y., Shi, D., Huang, H., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00732-4 · Cited by 39
“…increased after T cells activation or treating with ICIs [96], while EZH2 inhibitors combined with ICIs increased the expression of CXCL9 or CXCL10 [97] and the in fi ltration of Teffs [98, 99], enhanced the activity of CD4 + Teffs and CD8 + Teffs [92, 95], increased the production of INF-γ (Fig.”
BackgroundOne-carbon metabolism shapes T cell immunity in cancer
Qiu, Y., Xie, E., Xu, H., Cheng, H., & Li, G. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.010 · Cited by 36
Epigenetic Strategies to Boost Cancer Immunotherapies
Barrero, M. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061108 · Cited by 33
“AZA treatment alone or in combination with other epigenetic inhibitors improves the therapeutic efficacy of anti-PD-L1 and anti-CTLA4 treatments in mouse models of melanoma and ovarian cancer [25,26].”
BackgroundApplications of Single-Cell Omics to Dissect Tumor Microenvironment
Guo, T., Li, W., & Cai, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.548719 · Cited by 36
Ou, J., Lei, P., Yang, Z., Yang, M. G., Luo, L.-M., Mo, H., Luo, G., & He, J. (2021) · Journal of Molecular Histology · doi:10.1007/s10735-021-09967-z · Cited by 34
Huang, J., Zhang, J., Guo, Z., Li, C., Tan, Z. W., Wang, J., Yang, J., & Xue, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741302 · Cited by 39
Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症:英文版 · doi:10.1002/cac2.12229 · Cited by 36
Kawase, K., Kawashima, S., Nagasaki, J., Inozume, T., Tanji, E., Kawazu, M., Hanazawa, T., & Togashi, Y. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0815 · Cited by 36
Yi, S., Sun, J., Qiu, L., Fu, W., Wang, A., Liu, X., Yang, Y., Kadin, M. E., Tu, P., & Wang, Y. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.10.036 · Cited by 35
HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
Liu, X., Wang, D., Zhang, R., Jin, T., Qu, L., Jin, Q., Zheng, J., Sun, J., Wu, Z., Wang, L., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00485 · Cited by 34
“Similar to other targeted therapeutics, treatment response might be especially prominent in patients with overexpressed HDAC10 (28, 36).”
BackgroundChanges of tumor microenvironment in non-small cell lung cancer after TKI treatments
Chen, S., Tang, J., Liu, F., Li, W., Yan, T., Shangguan, D., Yang, N., & Liao, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1094764 · Cited by 38
“For instance, CXC-chemokine ligand 10 (CXCL10), which could reportedly recruit CD8+ T cells (82), was downregulated (22) via the PI3K-AKT pathway in EGFR activation.”
BackgroundTargeting one‐carbon metabolism for cancer immunotherapy
Ren, X., Wang, X., Zheng, G., Wang, S., Wang, Q., Yuan, M., Xu, T., Xu, J., Huang, P. C., & Ge, M. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1521 · Cited by 39
“47,48 A study showed that DNMT1 might block the epigenetics of immune protective genes and then influence the clinical response to immunotherapy.”
BackgroundImmune checkpoint inhibitors: the new frontier in non–small cell lung cancer treatment
El-Osta, H. E., Shahid, K., Mills, G. M., & Peddi, P. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s111209 · Cited by 36
“78 Azacytidine upregulates multiple genes involved in immune system evasion, including PD-L1, in lung cancer cell lines.”
CAR T cell therapy: newer approaches to counter resistance and cost
Yadav, R. K., Ali, A., Kumar, S., Sharma, A., Baghchi, B., Singh, P., Das, S., Singh, C., & Sharma, S. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03779 · Cited by 35
“These chemokines are involved in trafficking of effector T cells to the tumor microenvironment [72], thus their low levels prevent the T cell function.”
BackgroundLi, Y., Wu, Y., & Hu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641883 · Cited by 34
“Progress has been made on developing epigenetic immunotherapy for cancer treatments (85, 87).”
BackgroundZhang, Z., Luo, L., Xing, C., Chen, Y., Xu, P., Mao, L., Zeng, L., Li, C., Ghosh, S., Manna, D. D., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00263-z · Cited by 34
Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors
Berland, L., Gabr, Z., Chang, M., Ilié, M., Hofman, V., Rignol, G., Ghiringhelli, F., Mograbi, B., Rashidian, M., & Hofman, P. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1384121 · Cited by 34
Wang, W., Wu, J., Ji, M. Q., & Wu, C. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02661-w · Cited by 31
Self-citationSerganova, I. S., Chakraborty, S., Yamshon, S., Isshiki, Y., Bucktrout, R., Melnick, A. M., Béguelin, W., & Zappasodi, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.805195 · Cited by 31
“EZH2 inactivation also contributes to the recruitment of CD4 and CD8 T cells into the TME by enhancing local Th1-type chemokine production (CXCL9, CXCL10), and loss of EZH2 has also been shown to increase Th2-type cytokine production (Tumes et al., 2013; Peng et al., 2015).”
BackgroundEpigenetics of Dendritic Cells in Tumor Immunology
Godoy‐Tena, G., & Ballestar, E. (2022) · Cancers · doi:10.3390/cancers14051179 · Cited by 31
“Another study also showed that PGE2 induces the upregulation of DNMTs and DNA hypermethylation of several genes [133].”
BackgroundInfluentialAdoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
Zhu, Y., Zhou, J., Zhu, L., Hu, W., Liu, B., & Xie, L. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2060019 · Cited by 31
“methylation can reduce T cell vitality, immune cells secrete cytokines disorder, and Treg cell activation.(81) DNA methyltransferase inhibitors (DNMTi) can enhance the cytotoxicity of CD8 + T cells, as well as assist CD4 + T cells by inducing the expression of key immunostimulatory cytokines.”
BackgroundYan, J., Chen, Y., Patel, A. J., Warda, S., Lee, C. J., Nixon, B. G., Wong, E. W. P., Miranda-Román, M. A., Yang, N., Wang, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153437 · Cited by 33
“We further validated the decreased protein expression of MHC-I, B2M, and MHC-II by IHC in PRC2loss tumors using an MPNST tissue microarray (TMA) (Figure 2, C tumor microenvironment (TME) and tumor responses to immunotherapy (28).”
MethodQiu, J., Sharma, S., Rollins, R. A., & Paul, T. A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0072 · Cited by 31
Epigenetics and immunotherapy in colorectal cancer: progress and promise
Dang, T., Guan, X., Cui, L., Ruan, Y., Chen, Z., Zou, H., Lan, Y., Liu, C., & Zhang, Y. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01740-9 · Cited by 31
“DNMT1 suppresses chemokines expression, such as CXCL-9/10, which are essential for CD8 + T-cell migration [19].”
BackgroundThe current and emerging immunotherapy paradigm in small-cell lung cancer
Qin, K., Gay, C. M., Byers, L. A., & Zhang, J. J. (2025) · Nature Cancer · doi:10.1038/s43018-025-00992-5 · Cited by 36
“These modifications can have important implications for the effectiveness of immunotherapy 139–142 .”
Epigenomics-Guided Drug Development: Recent Advances in Solving the Cancer Treatment “jigsaw puzzle”
Dzobo, K. (2019) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0206 · Cited by 29
“GSK126, an EZH2 inhibitor, can also increase the efficacy of immune checkpoint inhibitors (Peng et al., 2015).”
Kang, T. G., Park, H. J., Moon, J., Lee, J. H., & Ha, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e23 · Cited by 36
Hu, N., Li, W., Hong, Y., Zeng, Z., Zhang, J., Wu, X., Zhou, K., & Wu, F. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.12.006 · Cited by 31
“For example, Peng et al.25 showed that DAC upregulates tumor CXCL10, increasing effector T cells in the TME and improving response to aPDL1 treatment.”
BackgroundLin, S., Tu, G., Yu, Z., Jiang, Q., Zhang, L., Liu, J., Liu, Q., Huang, X., Xu, J., Lin, Y., et al. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116912 · Cited by 30
Characterizing crosstalk in epigenetic signaling to understand disease physiology
Lempiäinen, J. K., & Garcia, B. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220550 · Cited by 30
Molecular principles of tissue invasion and metastasis
Dhanisha, S. S., & Guruvayoorappan, C. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00348.2022 · Cited by 31
Zhang, Y., Mei, Q., Liu, Y., Li, X., Brock, M. V., Chen, M., Dong, L., Shi, L., Wang, Y., Guo, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1323619 · Cited by 31
Chen, J. A., Ma, W., Yuan, J. D., & Li, T. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_9 · Cited by 31
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
Fenton, S. E., Sosman, J. A., & Chandra, S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.28 · Cited by 37
“Additionally, upregulation of EZH2 expression causes CXCL9 and CXCL10 downregulation, decreasing T cell recruitment to the tumor, and promotes the tumor cells to undergo transformation to a more mesenchymal phenotype([126-132]).”
BackgroundHanel, W. G., & Epperla, N. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01113-2 · Cited by 29
“EZH2 may also have immune modulatory effects wherein it suppresses the immune effector trafficking by repressing Th1 type cytokines [58].”
BackgroundMiyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 35
Empowering the Potential of CAR-T Cell Immunotherapies by Epigenetic Reprogramming
Alvanou, M., Lysandrou, M., Christofi, P., Psatha, N., Spyridonidis, A., Παπαδοπούλου, Α., & Yannaki, E. (2023) · Cancers · doi:10.3390/cancers15071935 · Cited by 32
Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges
Mondello, A., Bo, M. D., Toffoli, G., & Polano, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1260276 · Cited by 35
“…some histone modi fi cations, such as reduced lysine acetylation and methylation, may act as prognostic biomarkers in breast cancer (Elsheikh et al., 2009; Zhou et al., 2022) or they may predict response to treatment, as in the case of immunotherapy (Peng et al., 2015; Hoffmann et al., 2023).”
BackgroundLiu, K. G., Gupta, S., & Goel, S. (2016) · Oncotarget · doi:10.18632/oncotarget.14388 · Cited by 28
“Based on these principles, recent research have shown that increasing effector T cells tumor infiltration may improve the efficacy of PD-L1 checkpoint blockade [66].”
BackgroundMola, S., Pinton, G., Erreni, M., Corazzari, M., Andrea, M. D., Grolla, A. A., Martini, V., Moro, L., & Porta, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094391 · Cited by 29
“Therefore, EZH2 inhibition alone or in combination with immune checkpoints has been found to be associated with enhanced CD8 T cell infiltration and antitumor immunity [23,24,61,62].”
BackgroundTumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
García-Domínguez, D. J., Hontecillas‐Prieto, L., Carrión, N. P., Jiménez‐Cortegana, C., Sánchez‐Margalet, V., & de la Cruz‐Merino, L. (2022) · Cancers · doi:10.3390/cancers14061469 · Cited by 32
“DNA methylation by DNMT1 and H3K27 trimethylation by EZH2 have been found to impair T-cell infiltration in the TME [189].”
BackgroundMa, X., Wu, J., Wang, B., Liu, C., Liu, L., & Sun, C. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5424 · Cited by 30
Challenges and exploration for immunotherapies targeting cold colorectal cancer
Li, D., Tang, Y., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i1.55 · Cited by 30
Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies
Ratnam, N. M., Sonnemann, H. M., Frederico, S. C., Chen, H. A., Hutchinson, M.-K. N. D., Dowdy, T., Reid, C. M., Jung, J., Zhang, W., Song, H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719091 · Cited by 28
Regulation of histone H3K27 methylation in inflammation and cancer
Ma, J., Zhang, Y., Li, J., Dang, Y., & Hu, D. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00254-x · Cited by 30
“Conversely, combining EZH2 and DNA methyltransferase inhibitors with PD-L1 blockade therapy enhances immune cell infiltration and suppresses tumor growth [157].”
Pémille, C. V. D., Berzero, G., Small, M., Psimaras, D., Giry, M., Daniau, M., Sanson, M., Delattre, J., Honnorat, J., Desestret, V., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0125-7 · Cited by 26
An effective cell-penetrating antibody delivery platform
Herrmann, A., Nagao, T., Zhang, C., Lahtz, C., Li, Y., Yue, C., Mülfarth, R. I., & Yu, H. (2019) · JCI Insight · doi:10.1172/jci.insight.127474 · Cited by 29
Addressing Resistance to Immune Checkpoint Inhibitor Therapy: An Urgent Unmet Need
Hu‐Lieskovan, S., Malouf, G. G., Jacobs, I. A., Chou, J., Liu, L., & Johnson, M. L. (2021) · Future Oncology · doi:10.2217/fon-2020-0967 · Cited by 32
Epigenetic Regulation of Cancer Immune Cells
Patino, D. M. A., Radhakrishnan, V., Suvilesh, K. N., Manjunath, Y., Li, G., Kimchi, E. T., Staveley-O’Carroll, K. F., Warren, W. C., Kaifi, J. T., & Mitchem, J. B. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.022 · Cited by 27
Hong, J., Lee, J. H., Zhang, Z., Wu, Y., Yang, M., Liao, Y., de la Rosa, R., Scheirer, J. L., Pechacek, D., Zhang, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0736 · Cited by 29
Epigenetic Perspective of Immunotherapy for Cancers
Keshari, S., Barrodia, P., & Singh, A. K. (2023) · Cells · doi:10.3390/cells12030365 · Cited by 29
“In the TIME, cancer cells escape immune-mediated cell death by utilizing epigenetic mechanisms to escape host immune recognition and immunogenicity [31,32].”
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges
Alfayez, M., & Borthakur, G. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1459184 · Cited by 27
“Also in ovarian cancer, HMAs induces CXCL-9 and CXCL-10 which lead to CTCs infiltration of the tumor nest [109].”
BackgroundJin, M., Duan, J., Liu, W., Ji, J., Liu, B., & Zhang, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01897-w · Cited by 30
“This approach yielded many known EZH2 substrate genes, such as IRF1 [15], CXCL10 [16] and SOX9 [17], as well as several previously unknown putative substrate genes, such as CLOCK and TNFRSF11A (Fig.”
BackgroundZhang, Z., Li, C., Liao, W., Huang, Y., & Wang, Z. (2022) · Cancers · doi:10.3390/cancers14153619 · Cited by 25
“Moreover, other work has demonstrated that molecules involved in epigenetic modifications can modulate tumor antigen expression [21] or suppress T-cell infiltration in tumors [22,23] and, therefore, comprise additional candidates for combinations with checkpoint inhibitors.”
BackgroundAkce, M., El‐Rayes, B. F., & Wajapeyee, N. (2023) · Oncogene · doi:10.1038/s41388-023-02646-1 · Cited by 26
“Epigenetic silencing of genes associated with T-cell trafficking and function also contributes to immune tolerance in HCC [15, 21, 22].”
BackgroundThe multiple faces of cGAS-STING in antitumor immunity: prospects and challenges
Zhou, Z., Huang, S., Fan, F., Xu, Y., Moore, C., Li, S., & Han, C. (2024) · Medical Review · doi:10.1515/mr-2023-0061 · Cited by 26
“In addition, IFN-I also upregulates the expression of multiple chemokines such as C-X-C motif chemokine ligand 9 (CXCL9) and CXCL10, which promote the in fi ltration of APCs and e ff ector T (Te ff ) cells [32, 142, 143].”
BackgroundEpigenetic and genetic deregulation in cancer target distinct signaling pathway domains
Gao, Y., & Teschendorff, A. E. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1100 · Cited by 25
“Given their role in suppressing specific Th1-type chemokines in ovarian cancer (47), we asked if DNAm patterns of epigenetically deregulated genes in the chemokine signaling pathway were significantly correlated (or anti-correlated) with expression of either DNMT1 or EZH2, and how this varied across cancer-types.”
BackgroundTazzari, M., Brich, S., Tuccitto, A., Bozzi, F., Beretta, V., Spagnuolo, R. D., Negri, T., Stacchiotti, S., Deraco, M., Baratti, D., et al. (2018) · Journal of Immunology Research · doi:10.1155/2018/5804230 · Cited by 26
“EZH2 expressed by tumour cells has been reported to subvert the cytokine milieu, limit the recruitment of Th1 effectors, and ultimately favour immunoevasion [9, 10].”
BackgroundPatient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway
Haake, K., Neehus, A., Buchegger, T., Kühnel, M., Blank, P., Philipp, F., Oleaga‐Quintas, C., Schulz, A., Grimley, M. S., Goethe, R., et al. (2020) · Cells · doi:10.3390/cells9020483 · Cited by 25
“The following primers were used for SYBR qR-TPCR: GAPDH (#QT01192646 Qiagen, Hilden, Germany), IRF1 (#QT00494536 Qiagen), CCL2 (#QT00212730 Qiagen), CCL4 (#QT01008070 Qiagen), CXCL10 [36].”
Impact of anatomic site on antigen-presenting cells in cancer
Zagorulya, M., Duong, E., & Spranger, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001204 · Cited by 27
Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential
Maes, K., Mondino, A., Lasarte, J. J., Agirre, X., Vanderkerken, K., Prósper, F., & Breckpot, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652160 · Cited by 26
Tatsuguchi, T., Uruno, T., Sugiura, Y., Sakata, D., Izumi, Y., Sakurai, T., Hattori, Y., Oki, E., Kubota, N., Nishimoto, K., et al. (2022) · International Immunology · doi:10.1093/intimm/dxac002 · Cited by 27
“So far, it has been proposed that epigenetic silencing of the genes encoding chemokines in the tumor microenvironments and oncogenic pathways in tumors such as WNT/-catenin signaling are associated with T cell exclusion (4, 8-11).”
Metadata
- Authors
- Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., Kotarski, J., Tarkowski, R., Dou, Y., Cho, K., Hensley-Alford, S., Munkarah, A., Liu, R., & Zou, W.
- Affiliations
- University of Michigan (US)
- Medical University of Lublin (PL)
- Henry Ford Health (US)
- Corresponding author
- Zou, Weiping
- ORCID
- Venue
- Nature
- Published
- 2015-10-26
- Volume
- 527
- Issue
- 7577
- Pages
- 249-253
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4779053
- OpenAlex
- W2103021272
- Cited by
- 1,201
- References
- 37
- Citations by year
- 2026: 79 · 2025: 100 · 2024: 104 · 2023: 132 · 2022: 155 · 2021: 159 · 2020: 125 · 2019: 109 · 2018: 85 · 2017: 89 · 2016: 61 · 2015: 2
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (CA099985, R01CA123088, R01CA152470, CA193136, R01CA156685, CA123088, 5P30 CA 46592, CA156685, CA152470, R01CA171306, R01CA193136, CA171306, R01CA099985, F31CA189440, R01CA190176, CA190176, P30CA046592)
- National Institute of General Medical Sciences (R01GM082856)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- epigenetic silencing, EZH2, DNMT1, CXCL9, CXCL10, ovarian cancer, tumor immunosuppression, adoptive T cell therapy, CD8+ T cells, H3K27me3, DNA methylation, histone modifications, tumor microenvironment, immunotherapy response
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, DNA (Cytosine-5-)-Methyltransferase 1, Animals, DNA (Cytosine-5-)-Methyltransferases, Female, Histones, Humans, Immunotherapy, Lysine, Ovarian Neoplasms, Prognosis, Tumor Cells, Cultured, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Th1 Cells, Chemokines, Tumor Escape, DNA Methylation, Gene Silencing, Xenograft Model Antitumor Assays, Epigenesis, Genetic, Mice, Chemokine CXCL10, Chemokine CXCL9, B7-H1 Antigen, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.